EUCTR2004-001456-36-IT进行中（未招募）不适用
A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 372
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and safety of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix™-IPV+Hib) vaccine in healthy Korean infants.Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.EUCTR2012-004137-16-Outside-EU/EEAGlaxoSmithKline Biologicals454
进行中（未招募）
不适用
A phase III randomized, open-label, multi-center study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have suboptimal cytogenetic response (CyR) on imatinib - NDChronic Myelogenous Leukemia (CML) Ph+ chronic phaseMedDRA version: 6.1Level: PTClassification code 10009013EUCTR2005-005047-26-ITOVARTIS FARMA608
进行中（未招募）
不适用
A phase III randomized, open-label, multi-center study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have suboptimal cytogenetic response (CyR) on imatinib.EUCTR2005-005047-26-DEovartis Pharma Services AG608
已完成
3 期
A phase III randomized, open-label, multi-center study of nilotinib versus imatinib in adult patients with philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have suboptimal cytogenetic response (CyR) ib unatububChronic myeloid leukemia (CML)10024324NL-OMON31183Medisch Spectrum Twente5
进行中（未招募）
1 期
Study to evaluate immunogenicity and safety study of GSK Biologicals’ Herpes Zoster (HZ) vaccine GSK1437173A when co-administered with Pneumovax 23 in adults aged 50 years and older.Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults = 50 years of age [YOA ] and immunocompromised adults = 18 YOA.)MedDRA version: 17.0Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-005314-19-EEGlaxoSmithKline Biologicals864